Hennion & Walsh Asset Management Inc. Purchases 57,088 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Hennion & Walsh Asset Management Inc. grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 45.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,966 shares of the company’s stock after buying an additional 57,088 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.26% of Kiniksa Pharmaceuticals worth $3,397,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in KNSA. Essex Investment Management Co. LLC lifted its holdings in Kiniksa Pharmaceuticals by 0.5% during the first quarter. Essex Investment Management Co. LLC now owns 172,740 shares of the company’s stock valued at $3,408,000 after purchasing an additional 850 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals by 5.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock valued at $413,000 after buying an additional 1,153 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Kiniksa Pharmaceuticals by 8.1% in the 1st quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock worth $378,000 after buying an additional 1,435 shares during the period. Los Angeles Capital Management LLC grew its stake in Kiniksa Pharmaceuticals by 1.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 147,182 shares of the company’s stock valued at $2,582,000 after buying an additional 1,540 shares in the last quarter. Finally, QRG Capital Management Inc. increased its position in shares of Kiniksa Pharmaceuticals by 11.7% during the fourth quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock valued at $281,000 after buying an additional 1,679 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $26.63 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $27.88. The stock has a market cap of $1.89 billion, a P/E ratio of 242.09 and a beta of 0.38. The firm’s fifty day moving average price is $21.82 and its 200-day moving average price is $20.19.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The business had revenue of $108.30 million for the quarter, compared to the consensus estimate of $90.60 million. During the same quarter last year, the business posted ($0.02) earnings per share. The company’s revenue for the quarter was up 51.5% on a year-over-year basis. On average, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.05 earnings per share for the current year.

Analysts Set New Price Targets

KNSA has been the topic of a number of analyst reports. Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, May 3rd. They set an “overweight” rating and a $34.00 target price on the stock. Evercore ISI increased their price objective on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Wedbush boosted their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.00.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the sale, the chief executive officer now owns 63,012 shares of the company’s stock, valued at $1,616,257.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the sale, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at $1,616,257.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Ragosa sold 24,248 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $24.79, for a total transaction of $601,107.92. Following the sale, the chief financial officer now owns 19,253 shares of the company’s stock, valued at $477,281.87. The disclosure for this sale can be found here. In the last three months, insiders have sold 182,372 shares of company stock valued at $4,671,729. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.